% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@PHDTHESIS{Zhou:282313,
author = {Zhou, Jiayin},
title = {{G}ene-expression control in early and late-onset dementia},
school = {Georg-August-Universität Göttingen},
type = {Dissertation},
reportid = {DZNE-2025-01283},
pages = {155 p.},
year = {2022},
note = {Dissertation, Georg-August-Universität Göttingen, 2022},
abstract = {Mutations in genes that control epigenetic gene expression,
especially the machinery that controls Histone 3 lysine 4
(H3K4me) methylation, are over-represented in intellectual
disability disorders. It is mediated by both lysine
methyltransferases and demethylases. Dysregulation of these
enzymes is closely associated with cognitive dysfunction in
humans. Moreover, there is evidence that H3K4me3 levels
decrease in neurodegenerative diseases such as Alzheimer’s
disease and previous studies demonstrated that H3K4me
demethylases (KDMs) are important targets for cognitive
functions. In the first study, we specifically tested the
therapeutic potential of H3K4me demethylases (KDMs) in vitro
and in vivo. Our data suggest that decreasing the levels of
KMD5B can improve neuronal synapse plasticity and reduce
inflammatory responses. When we downregulated the KDM5B in
aged mice, it helps to rescue their learning and memory
abilities. Furthermore, inhibition of KDM5B in mouse models
for age-associated memory decline or amyloid deposition also
ameliorated memory impairment. Our data strongly suggest
that H3K4me demethylases, represented by KDM5B, have great
potential to become therapeutic targets for the treatment of
cognitive disorders. Additionally, Frontotemporal
degeneration is the second most common type after
Alzheimer’s disease, sharing pathophysiological mechanisms
and genetic origins with some dementia-specific disorders.
Mining FTD-associated microRNAs can be used to distinguish
FTD from other dementia-specific disorders. Thus in the
second study, we established an in-depth smallRNAome
sequencing analysis of frontal and temporal cortex tissue to
identify specific microRNAs that showed dysregulation in a
group of FTD patients. Further analysis was performed by
manipulating one of these signatures, miR-129-5p, to reflect
the molecular changes that occur during brain pathology in
vitro. The impact of inhibition of miR-129-5p markers on
cognitive impairment was also revealed in animals,
suggesting its use as a powerful pathogenetic indicator of
FTD-related disorders.},
cin = {AG Fischer},
cid = {I:(DE-2719)1410002},
pnm = {352 - Disease Mechanisms (POF4-352)},
pid = {G:(DE-HGF)POF4-352},
typ = {PUB:(DE-HGF)11},
url = {https://pub.dzne.de/record/282313},
}